Targeted Drug Delivery with Protein Nanosyringes

In this episode, we talk to Dr Joe Healey, CEO of NanoSyrinx, a University of Warwick spin-out leveraging naturally occurring protein nanosyringes to encapsulate and deliver biologic therapeutics to the interior of cells. Their synthetic biology approach is revolutionizing how medicines are administered on a nanoscopic scale, improving therapeutic efficacy and enabling access to a wide array of previously inaccessible therapeutic targets.

Joe has a background in molecular and synthetic biology, and founded NanoSyrinx during his PhD at the University of Warwick. Last year, he successfully led NanoSyrinx’s oversubscribed £6.2M seed+ investment round to fund the application of their technology across a range of therapeutics and work towards building a pipeline of clinical targets to take forward in their next phase of growth.

Joe tells us about their bacteria based platform, his experiences securing support to take the technology forward and how his interest in being a CEO evolved as he led the commercial application of his research.